<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.104098</article-id><article-id pub-id-type="publisher-id">ACM-35332</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200400000_46985045.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肿瘤心脏病学及老年肿瘤患者抗肿瘤治疗相关心血管毒性研究进展
  Advances in the Study of Cardio-Oncology and Cardiovascular Toxicity Related to Tumor Cardiology in Elderly Cancer Patients
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>余</surname><given-names>其贵</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谢</surname><given-names>军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>安徽医科大学附属合肥医院，安徽 合肥</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>04</month><year>2020</year></pub-date><volume>10</volume><issue>04</issue><fpage>629</fpage><lpage>635</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  随着人口老龄化、生活方式及饮食习惯不断改变，近年来肿瘤发病率呈逐渐增高趋势，同时随着医疗技术不断进步，癌症治疗水平不断提高，使得肿瘤患者的治愈率不断提高，患者生存时间和生活质量均得到显著提高。但是无论现有的和新兴的癌症治疗方法都会对患者的心血管系统产生毒性作用，从而影响其心血管健康，进而引起患者原有心脏病恶化或心法心血管事件，导致肿瘤患者长期发病率和死亡率明显增加，日益成为影响这类疾病预后的关键因素。对于此类患者在保证患者最有效的癌症治疗的同时，促进患者的心血管健康，最大限度降低抗肿瘤治疗心血管毒性、保护心血管系统功能，是未来研究及发展方向。
   With the aging of the population and the changes of lifestyle and eating habits in recent years, the incidence of cancer increased gradually, at the same time as medical technology continues to progress, and constantly improve the level of treatment of cancer, the tumor cure rate of patients with increasing survival time and quality of life are improved significantly. But both existing and emerging cancer treatment will produce toxic effects on the cardiovascular system, thus affecting the cardiovascular health, and patients with heart disease caused by the original deterioration or heart cardiovascular events, resulting in long-term morbidity and mortality of cancer patients in-creased significantly, has increasingly become the key factors affecting the prognosis of the disease. For such patients, while ensuring the most effective cancer treatment for patients, it is also the direction of future research and development to promote cardiovascular health of patients, minimize cardiovascular toxicity and protect cardiovascular system function.
 
</p></abstract><kwd-group><kwd>肿瘤心脏病学，抗肿瘤治疗，心血管毒性，研究进展, Cardio-Oncology</kwd><kwd> Cancer Treatment</kwd><kwd> Cardiovascular Toxicity</kwd><kwd> Advance</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>肿瘤心脏病学及老年肿瘤患者抗肿瘤治疗相关心血管毒性研究进展<sup> </sup></title><p>余其贵<sup>1,2</sup>，谢军<sup>1,2</sup></p><p><sup>1</sup>安徽医科大学附属合肥医院，安徽 合肥</p><p><sup>2</sup>合肥市第二人民医院全科医学科，安徽 合肥</p><p>收稿日期：2020年4月5日；录用日期：2020年4月21日；发布日期：2020年4月28日</p><disp-formula id="hanspub.35332-formula53"><graphic xlink:href="//html.hanspub.org/file/25-1571236x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>随着人口老龄化、生活方式及饮食习惯不断改变，近年来肿瘤发病率呈逐渐增高趋势，同时随着医疗技术不断进步，癌症治疗水平不断提高，使得肿瘤患者的治愈率不断提高，患者生存时间和生活质量均得到显著提高。但是无论现有的和新兴的癌症治疗方法都会对患者的心血管系统产生毒性作用，从而影响其心血管健康，进而引起患者原有心脏病恶化或心法心血管事件，导致肿瘤患者长期发病率和死亡率明显增加，日益成为影响这类疾病预后的关键因素。对于此类患者在保证患者最有效的癌症治疗的同时，促进患者的心血管健康，最大限度降低抗肿瘤治疗心血管毒性、保护心血管系统功能，是未来研究及发展方向。</p><p>关键词 :肿瘤心脏病学，抗肿瘤治疗，心血管毒性，研究进展</p><disp-formula id="hanspub.35332-formula54"><graphic xlink:href="//html.hanspub.org/file/25-1571236x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/25-1571236x7_hanspub.png" /> <img src="//html.hanspub.org/file/25-1571236x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>近年来随着医学研究和医学治疗手段不断进步，特别是肿瘤治疗的手段和技术更是有了质的飞跃，癌症患者生存率明显提高并且每年保持稳定的增长。但同时多样的治疗方法更使得肿瘤患者出现心血管方面的并发症或原有心脏病恶化。肿瘤患者生存率和死亡率受到其心血管疾病的严重影响。大量的研究证据证实癌症和心脏病之间存在重要联系，特别是在老年人群中两者之间存在共同的危险因素，包括在肿瘤治疗过程中对心血管产生不利影响。对于肿瘤患者合并有心血管基础疾病一部分患者，肿瘤心脏病学的研究也可以同时为这部分人群治疗手段的抉择提供必要的利弊分析。因此对肿瘤心脏病学的认识和研究对于临床肿瘤患者的综合治疗与预后判断是十分必要的。</p><p>随着医疗技术不断进步，癌症治疗方法从原来单纯的普通化疗、放疗逐渐发展成为包括放疗、化疗、免疫和靶向治疗、综合治疗等，然而上述治疗都会导致一定程度的心血管毒副作用甚至持久性心脏损害，威胁患者健康甚至导致死亡。肿瘤心脏病学(Cardio-Oncology或Onco-Cardiology)指是从患者肿瘤疾病确诊开始，研究患者与肿瘤相关存在的一系列关于心血管疾病的危险分层、预防和治疗的一门学科；它在临床治疗过程中需要紧密结合心脏病学及肿瘤学两个领域的相关理论和经验，是一门跨专业、多学科融合的一门临床学科 [<xref ref-type="bibr" rid="hanspub.35332-ref1">1</xref>]，随着生活水平提高及医疗技术进步，癌症患者生存时间越来越长，部分癌症患者甚至可达到临床缓解；但是肿瘤治疗相关的心血管并发症对癌症患者存活时间有显著影响 [<xref ref-type="bibr" rid="hanspub.35332-ref2">2</xref>]，因此肿瘤心脏病学或称“心脏肿瘤学”受到相关临床专家的日益关注。</p><p>目前临床把肿瘤治疗相关的心脏毒性主要分为两大类，包括化疗和放疗相关的心脏毒性。据临床特点，化疗相关的心脏毒性又可分为两类：I型和II型。I型化疗相关心脏毒性主要是由蒽环类药物引起，其特点表现为：剂量依赖的心肌坏死和大面积不可逆损伤；II型化疗相关心脏毒性表现为心肌可逆性的损伤，与药物剂量无关，也无细胞坏死 [<xref ref-type="bibr" rid="hanspub.35332-ref3">3</xref>]，通常是由分子靶向治疗药物导致的。《2016欧洲心脏病学会癌症治疗与心血管毒性实用指南》将肿瘤治疗相关心血管毒性分为九大类，分别是：心功能不全和心力衰竭、冠状动脉性心脏病、高血压、心律失常、瓣膜疾病、肺动脉高压、血栓栓塞性疾病、周围血管病和卒中以及其他心血管疾病 [<xref ref-type="bibr" rid="hanspub.35332-ref4">4</xref>]。本文就老年肿瘤患者肿瘤治疗相关常见心血管毒性的分类及综合管理作一综述，为老年人群特别是合并有心脏基础疾病人群在抗肿瘤治疗过程中预防抗肿瘤相关心脏损害提供参考。</p></sec><sec id="s4"><title>2. 抗肿瘤治疗相关心功能不全</title><p>老年人群为心脏病或心功能不全高发人群，其心脏自身储备功能下降，极易出现功能失代偿；老年肿瘤患者在肿瘤治疗过程中心功能不全或心衰通常是最常见也是最严重的并发症，其严重影响老年肿瘤患者生活质量和预后 [<xref ref-type="bibr" rid="hanspub.35332-ref3">3</xref>]。临床主要化疗药物为蒽环类药物，此类药物对心脏毒性具有剂量依赖性，据临床特点可分为急性、早发慢性进展和晚发慢性进展3种类型，其首发表现为左室射血分数(LVEF)下降，部分病人可伴有生物标志物如B型尿钠肽(BNP)和肌钙蛋白增高，提示该类患者心脏毒性风险增加 [<xref ref-type="bibr" rid="hanspub.35332-ref5">5</xref>]；患者早期可无不适反应，但随着化疗药剂量累积，可逐步进展为不可逆心力衰竭。目前研究认为该类药物产生心脏毒性主要可能机制包括 [<xref ref-type="bibr" rid="hanspub.35332-ref6">6</xref>]：1) 心肌氧化应激损伤：主要由蒽环类醌基团氧化还原反应引起的；2) 心肌细胞及线粒体钙稳态失衡；3) 心肌细胞超微结构蛋白降解和线粒体能量破坏；4) 阻碍拓扑异构酶IIB损伤DNA，或诱发细胞生存信号传导通路损伤；5) 对心脏祖细胞的直接细胞毒效益，导致心肌修复能力下降；综上机制引起心肌细胞毒性反应，引起心肌坏死或凋亡，心脏减退出现失代偿，最终导致心力衰竭。</p><p>肿瘤治疗相关的心功能不全干预主要目的是维持左室射血分数正常，延缓心室重构。目前国际公认标准LVEF &lt; 50%为异常，因此在抗肿瘤治疗过程中，特别是是对曾有心血管毒性药物和胸部放疗史患者，除监测LVEF外，目前主张联合BNP及肌钙蛋白检测识别高危患者 [<xref ref-type="bibr" rid="hanspub.35332-ref7">7</xref>]。对化疗药物特别是蒽环类药物等心脏毒性的预防：一方面通过限制剂量、持续静脉滴注来降低药物峰浓度，减轻心脏毒性，另一方面可通过对药物进行修饰来减轻心脏毒性作用；同时推荐所有LVEF小于50%肿瘤患者使用ACEI (或ARB)类药物及β受体阻滞剂 [<xref ref-type="bibr" rid="hanspub.35332-ref8">8</xref>] 抑制心肌重构、保护心功能。</p></sec><sec id="s5"><title>3. 老年肿瘤治疗相关冠状动脉性心脏病</title><p>老年患者往往合并有冠状动脉硬化性心脏病，临床上多为无症状型；对于老年肿瘤合并无症状型冠心病患者，在肿瘤治疗前要做好充分评估内容包括既往史、吸烟史，及放化疗史等；并完善相关检查包括十二导联心电图、超声心动图，必要时考虑行有创性检查如冠状动脉造影，力求早发现早干预。</p><p>肿瘤治疗相关的冠状动脉性心脏病主要包括不稳定性心绞痛和急性心肌梗死。常见药物主要是抗代谢药5-氟尿嘧啶(5-fu)、卡培他滨等；研究发现 [<xref ref-type="bibr" rid="hanspub.35332-ref9">9</xref>] 在接受5-fu治疗患者中约10%~20%可发生心脏毒性事件，最常见症状为胸痛及心电图改变，严重者可出现心肌梗死和心律失常特别是对于有基础心脏病、接受放疗或蒽环类药物治疗的高危患者更需谨慎；其机制主要考虑是药物导致血管痉挛和血管内皮损伤，引起血管狭窄、凝血功能失常、急性血栓形成，导致心肌缺血/坏死 [<xref ref-type="bibr" rid="hanspub.35332-ref10">10</xref>]。对于触发冠脉痉挛患者，临床使用硝酸酯类药物和钙离子拮抗剂治疗可缓解症状；但针对反复发作患者或长期口服预防此类损害目前尚无明确定论 [<xref ref-type="bibr" rid="hanspub.35332-ref11">11</xref>]。</p></sec><sec id="s6"><title>4. 抗肿瘤治疗相关高血压</title><p>高血压发病率随年龄增加逐渐增高，而高血压又是癌症患者特别是老年癌症患者中最常见合并症。在癌症治疗过程中，尤其是接受化疗的患者，高血压发病率高达37%，究其原因考虑与抗癌药物对血压影响或抗癌机制本身引起高血压发生。随着癌症治疗技术不断进步出现许多新的治疗手段及药物，同时也催生了一些新的心血管并发症，特别是抑制血管内皮生长因子(VEGF)信号传导通路的新型靶向药物与高血压发生密切相关。该类新型靶向治疗药物包括单克隆抗体和酪氨酸激酶抑制剂(TKI)，其通过阻断血管生长所需的信号通路中的部分环节发挥作用。如贝伐珠单抗是一种单克隆抗体，其可与VEGF抑制其生物活性，该药被批准广泛用于多种实体肿瘤治疗，是抗血管生成重要治疗药物 [<xref ref-type="bibr" rid="hanspub.35332-ref12">12</xref>]。贝伐珠单抗是诱发高血压的抗癌代表药物。研究发现使用贝伐珠单抗患者约4%~35%出现不同级别高血压，其中约10%~20%患者可达3级高血压水平 [<xref ref-type="bibr" rid="hanspub.35332-ref13">13</xref>]。同类药物如舒尼替尼、索拉非尼等也可引起不同程度高血压。对于其导致高血压发生机制主要考虑为：1) TKI抑制VEGF通路，降低一氧化氮合酶活性，降低NO水平，导致血管收缩、血压增高 [<xref ref-type="bibr" rid="hanspub.35332-ref14">14</xref>]；2) 刺激血管和肾的内皮素合成增加 [<xref ref-type="bibr" rid="hanspub.35332-ref15">15</xref>]；3) 抑制血管生成、减少外周微血管，导致高血压发生 [<xref ref-type="bibr" rid="hanspub.35332-ref16">16</xref>]；其他可引起高血压的常用抗癌药物包括烷化剂、紫杉烷、神经内分泌药物及免疫抑制剂 [<xref ref-type="bibr" rid="hanspub.35332-ref17">17</xref>] 等。</p><p>抗肿瘤治疗相关高血压发生率和严重程度除与常见危险因素相关外，还与癌症分类、药物类型和剂量、药物治疗顺序及是否联合治疗等因素有关。抗肿瘤治疗相关高血压的治疗主要目标是减少靶器官损害，主要是心脏、脑及肾脏等重要器官；治疗策略上一是降低患者短期死亡风险，二是要确保新型抗血管生成药物临床疗效 [<xref ref-type="bibr" rid="hanspub.35332-ref18">18</xref>]。根据现有指南，合理选择抗高血压药物，实行个性化管理，保证血压达标同时兼顾各靶器官功能，动态监测血压。</p></sec><sec id="s7"><title>5. 抗肿瘤治疗相关心律失常</title><p>心律失常是肿瘤患者临床面临的一个常见问题，心律失常不仅影响肿瘤患者生活质量，同时限制患者对肿瘤治疗方案选择。抗肿瘤治疗可诱发多种类型的心律失常，其中包括心动过缓、心动过速和传导障碍；房颤是其最常见的类型，发生率可达15%左右 [<xref ref-type="bibr" rid="hanspub.35332-ref19">19</xref>]；严重时可引起快速型室性心律失常甚至危及生命 [<xref ref-type="bibr" rid="hanspub.35332-ref20">20</xref>]。常见药物为烷化剂如顺铂 [<xref ref-type="bibr" rid="hanspub.35332-ref21">21</xref>]，其病情严重程度与化疗药物剂量相关，部分心律失常呈可逆性。所有抗肿瘤治疗患者治疗前需行常规查十二导心电图检查了解QT间期，必要时计算校正的QT间期(QTC)；对心律失常高危人群包括心功能不全、甲状腺功能异常及合并心律失常患者建议进行动态监测心律 [<xref ref-type="bibr" rid="hanspub.35332-ref22">22</xref>]。针对患者实行个性化管理, 综合评估心脏猝死风险及患者生存期，选择适宜的抗心律失常药物或其他治疗手段包括介入治疗或起搏治疗等。</p></sec><sec id="s8"><title>6. 抗肿瘤治疗相关肺动脉高压</title><p>老年肿瘤患者在抗肿瘤治疗过程中可引起肺循环功能障碍，表现肺动脉压升高，引起肺动脉高压(PAH)，特别是老年肺癌化疗或放疗的患者，是一种严重的并发症；临床可表现为右心功能不全、右心功能衰竭等；临床常见抗肿瘤治疗药物如酪氨酸激酶抑制剂，该类药物所引起的PAH通常是可逆的；但对于严重的PAH患者往往需要停药或更换其他药物 [<xref ref-type="bibr" rid="hanspub.35332-ref23">23</xref>]；肺部肿瘤局部放疗在治疗同时往往可导致肺组织及附属血管损伤，引起肺毛细血管内皮损伤、导致血管闭塞或血栓形成，诱发肺循环阻力增加，导致肺高压；故在肿瘤治疗前通常行超声心动图评估患者右心功能，对于合并多种右心功能危险因素患者尽量做到早发现、早干预；通过NYHA心功能分级联合血浆N末端脑钠肽前体(NT-ProBNP)检查 [<xref ref-type="bibr" rid="hanspub.35332-ref24">24</xref>] 评估患者右心功能；治疗过程中动态随访及评估肺动脉压力；必要时可考虑行右心导管检查。</p></sec><sec id="s9"><title>7. 肿瘤治疗相关血栓性疾病</title><p>老年患者通常存在动脉硬化、血管内皮功能减退，为易栓人群；而老年肿瘤患者血液往往处于高凝状态，更易导致血栓形成。血栓栓塞常见部位可分为静脉血栓特别是深静脉及肺 [<xref ref-type="bibr" rid="hanspub.35332-ref25">25</xref>] 和动脉血栓如冠状动脉血栓事件；抗肿瘤药物往往造成血管内皮损伤，导致其抗凝功能减退，促使血栓形成 [<xref ref-type="bibr" rid="hanspub.35332-ref26">26</xref>]，同时化疗药物还可引起机体正常出凝血机制破坏，促进血栓形成。新型抗肿瘤药物如抗血管生成药或酪氨酸激酶抑制剂可引血栓形成或栓塞等动脉血栓事件，主要表现为急性冠脉综合征(ACS)、急性缺血性卒中或周围血管病，其中最常见的是冠状动脉缺血 [<xref ref-type="bibr" rid="hanspub.35332-ref27">27</xref>]；而临床常用免疫调节药物如沙利度胺或来那度胺等则以静脉血栓形成为主，表现为深静脉或肺栓塞 [<xref ref-type="bibr" rid="hanspub.35332-ref28">28</xref>]。肿瘤患者合并动脉血栓事件提示预后较差，对于接受VEGF抑制剂治疗患者则建议永久停止该类药物，部分医师推荐使用阿司匹林或氯比格雷预防性抗血小板治疗 [<xref ref-type="bibr" rid="hanspub.35332-ref29">29</xref>]；对于静脉血栓形成高危患者，临床常用华法林和低分子肝素作为首选治疗药物。对于合并静脉血栓的患者，在抗肿瘤治疗过程中是否行抗凝治疗，需根据患者临床表现、危险因素、获益与风险综合评估 [<xref ref-type="bibr" rid="hanspub.35332-ref30">30</xref>]。</p></sec><sec id="s10"><title>8. 抗肿瘤治疗相关瓣膜疾病</title><p>抗肿瘤相关瓣膜疾病主要是由放疗引起的，特别是合并有胸部放疗史、感染性心内膜炎、心功能不全和已知心脏瓣膜病变的高危患者。放疗能影响心脏全部机构包括心肌梗死、心脏瓣膜病、心包疾病、心律失常和放疗性心肌病等 [<xref ref-type="bibr" rid="hanspub.35332-ref31">31</xref>]。研究发现放疗最常见的是瓣膜损伤,常见瓣膜为二尖瓣部位；其损伤程度与放疗剂量呈正比 [<xref ref-type="bibr" rid="hanspub.35332-ref32">32</xref>]。对于老年患者、有胸部放疗的患者及心功能不全患者，在放疗前的基线评估及放疗后再评估显得十分重要；目前心脏超声检查是最主要的检查方法，特别是心脏彩超检查是评价二尖瓣病变的首选检查方法 [<xref ref-type="bibr" rid="hanspub.35332-ref33">33</xref>]。对于其放疗性心脏瓣膜病防治，一方面是联合其他新的治疗方法减少放疗剂量，另一方面是采取新的放疗技术、精准定为，减少心脏放疗野暴露，减轻心脏放疗损伤；同时对于心脏瓣膜疾病的治疗根据患者具体情况，可选择介入治疗或外科手术治疗等 [<xref ref-type="bibr" rid="hanspub.35332-ref34">34</xref>]。</p></sec><sec id="s11"><title>9. 抗肿瘤治疗相关周围血管病和卒中</title><p>抗肿瘤治疗往往会导致血管内皮损伤，特别是合并有糖尿病、高血脂及吸烟的患者，其发生外周血管病几率更高。常见的周围血管病(PAD)包括雷诺现象、缺血性卒中等，其主要机制是接受放射或化疗治疗导致血管内皮损伤，进而血栓形成 [<xref ref-type="bibr" rid="hanspub.35332-ref35">35</xref>]；常见的药物包括抗心血管生成药或顺铂等 [<xref ref-type="bibr" rid="hanspub.35332-ref36">36</xref>]。抗肿瘤治疗前通过血管超声或测量脉搏波传导速度/踝肱指数等来外周血管情况、评估周围血管疾病风险；对临床有症状患者，予抗血小板治疗，血管病变严重者，建议多学科包括血液科、肿瘤科、血管外科会诊，综合考虑制定个体化治疗方案 [<xref ref-type="bibr" rid="hanspub.35332-ref37">37</xref>]。对于无症状的患者，建议动态随访 [<xref ref-type="bibr" rid="hanspub.35332-ref38">38</xref>]。</p></sec><sec id="s12"><title>10. 抗肿瘤治疗相关其他心血管并发症</title><p>抗肿瘤相关其他心血管并发症包括心包疾病、心脏自主神经功能异常及胸腔积液；其常见于行放射治疗的患者。放射性心包炎通常首先表现为急性心包炎 [<xref ref-type="bibr" rid="hanspub.35332-ref39">39</xref>]，后逐步发展成慢性心包炎，表现为慢性心包积液或缩窄性心包炎；放疗可损伤心脏自主神经，导致自主神经功能异常 [<xref ref-type="bibr" rid="hanspub.35332-ref40">40</xref>]。临床可性心脏超声及CT常检查了解心包情况，对于急性心包炎，可使用非甾体类抗炎药及秋水仙碱治疗，严重时可行心包穿刺；而对于慢性或缩窄性心包炎则可考虑行心包剥离治疗。</p><p>综上所述，肿瘤患者在治疗期间出现心血管毒性反应，往往需要调整甚至停止抗肿瘤治疗，这将对临床预后产生深刻影响。随着对抗肿瘤相关心血管毒性发生机制理解的深入、危险分层工具的开发和应用，加强心脏科和肿瘤科医师之间积极合作，肿瘤心脏病学的格局将持续发展，能够早期识别心血管毒性，及时进行干预，则可让肿瘤治疗不致中断，从而挽救患者的生命 [<xref ref-type="bibr" rid="hanspub.35332-ref41">41</xref>]。相信在不远将来，通过肿瘤学家与心血管病学家组成多学科团队精诚合作、共同努力下，肿瘤心脏病学这个新兴领域将会持续发展，确保患者能够最大获益，最终改善癌症患者和生存者预后。</p></sec><sec id="s13"><title>文章引用</title><p>余其贵,谢 军. 肿瘤心脏病学及老年肿瘤患者抗肿瘤治疗相关心血管毒性研究进展Advances in the Study of Cardio-Oncology and Cardiovascular Toxicity Related to Tumor Cardiology in Elderly Cancer Patients[J]. 临床医学进展, 2020, 10(04): 629-635. https://doi.org/10.12677/ACM.2020.104098</p></sec><sec id="s14"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.35332-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Yeh, E.T. (2011) Onco-Cardiology: The Time Has Come. Texas Heart Institute Journal, 38, 246 -247.</mixed-citation></ref><ref id="hanspub.35332-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R., DeSantis, C., Virgo, K., et al. (2012) Cancer Treatment and Survivorship Statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 220-241. &lt;br&gt;https://doi.org/10.3322/caac.21149</mixed-citation></ref><ref id="hanspub.35332-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Zamorano, J.L., Lancellotti, P., Rodriguez, M.D., et al. (2016) 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed under the Auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC). European Journal of Heart Failure, 37, 2768-2801.</mixed-citation></ref><ref id="hanspub.35332-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Khouri, M.G., Douglas, P.S., Mackey, J., et al. (2012) Cancer Therapy-Induced Cardiac Toxicity in Early Breast Cancer: Addressing the Unresolved Issues. Circulation, 126, 2749-2763.  
&lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.112.100560</mixed-citation></ref><ref id="hanspub.35332-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Cardinale, D., Sandri, M.T., Colombo, A., et al. (2004) Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chem-otherapy. Circulation, 109, 2749-2754. 
&lt;br&gt;https://doi.org/10.1161/01.CIR.0000130926.51766.CC</mixed-citation></ref><ref id="hanspub.35332-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Hahn, V., Lenihan, D.J., Ky, B., et al. (2014) Cancer Therapy-Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies. Journal of the American Heart Association, 3, E000665.  
&lt;br&gt;https://doi.org/10.1161/JAHA.113.000665</mixed-citation></ref><ref id="hanspub.35332-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">黄恬. 心肌肌钙蛋白I在胸部肿瘤患者放疗时心肌损伤监测中的应用价值[J]. 河北医学, 2017, 23(6): 911-914.</mixed-citation></ref><ref id="hanspub.35332-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Copur, M.S. and Obermiller, A. (2011) An Algorithm for the Management of Hypertension in the Setting of Vascular Endothelial Growth Factor Signaling Inhibition. Clinical Col-orectal Cancer, 10, 151-156.  
&lt;br&gt;https://doi.org/10.1016/j.clcc.2011.03.021</mixed-citation></ref><ref id="hanspub.35332-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wacker, A., Lersch, C., Scherpinski, U., et al. (2003) High In-cidence of Angina Pectoris in Patients Treated with 5-Fluorouracil. A Planned Surveillance Study with 102 Patients. Oncology, 65, 108-112. 
&lt;br&gt;https://doi.org/10.1159/000072334</mixed-citation></ref><ref id="hanspub.35332-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Grunwald, M.R., Howie, L., Diaz Jr., L.A., et al. (2012) Takotsubo Car-diomyopathy and Fluorouracil: Case Report and Review of the Literature. Journal of Clinical Oncology, 30, e11-e14. &lt;br&gt;https://doi.org/10.1200/JCO.2011.38.5278</mixed-citation></ref><ref id="hanspub.35332-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Akpek, G. and Hartshorn, K.L. (1999) Failure of Oral Nitrate and Calcium Channel Blocker Therapy to Prevent 5-Fluorouracil--Related Myocardial Ischemia: A Case Report. Cancer Chemotherapy and Pharmacology, 43, 157-161. 
&lt;br&gt;https://doi.org/10.1007/s002800050877</mixed-citation></ref><ref id="hanspub.35332-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ferrara, N., Hillan, K.J. and Novotny, W. (2005) Bevacizumab (Avastin), a Humanized Anti-VEGF Mono-Clonal Antibody for Cancer Therapy. Biochemical and Biophysical Research Communications, 333, 328-235. 
&lt;br&gt;https://doi.org/10.1016/j.bbrc.2005.05.132</mixed-citation></ref><ref id="hanspub.35332-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Pande, A., Lombardo, J. and Spangenthal, E. (2007) Hypertension Secondary to Anti-Angiogenic Therapy: Experience with Bevacizumab. Anticancer Research, 27, 3465-3470.</mixed-citation></ref><ref id="hanspub.35332-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Dincer, M. and Altundag, K. (2006) Angiotension-Converting Enzyme Inhibitors for Bevacizumab-Induced Hypertension. Annals of Pharmacotherapy, 40, 2278-2279. &lt;br&gt;https://doi.org/10.1345/aph.1H244</mixed-citation></ref><ref id="hanspub.35332-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ksamba, T. and McDonald, D.M. (2007) Mechanisms of Adverse Effects of Anti-VEGF Therapy for Cancer. British Journal of Cancer, 96, 1788-1795. &lt;br&gt;https://doi.org/10.1038/sj.bjc.6603813</mixed-citation></ref><ref id="hanspub.35332-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Aparicio-Gallego, G., Afonso-Afonso, F.J., Leon-Mateos, L., et al. (2011) Molecular Basis of Hypertension Side Effects Induced by Sunitinib. Anticancer Drugs, 22, 1-8. &lt;br&gt;https://doi.org/10.1097/CAD.0b013e3283403806</mixed-citation></ref><ref id="hanspub.35332-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Porter, G.A., Bennett, W.M. and Sheps, S.C. (1990) Cy-closporine-Associated Hypertension. National High Blood Pressure Education Program. Archives of Internal Medicine, 150, 280-283.  
&lt;br&gt;https://doi.org/10.1001/archinte.1990.00390140036008</mixed-citation></ref><ref id="hanspub.35332-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Skoro-Sajer, N., Marta, G., Gerges, C., et al. (2014) Surgical Specimens, Haemodynamics and Long-Term Outcomes after Pulmonary Endarterectomy. Thorax, 69, 116-122. &lt;br&gt;https://doi.org/10.1136/thoraxjnl-2013-203746</mixed-citation></ref><ref id="hanspub.35332-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Yeh, E.T. and Bickford, C.L. (2009) Cardiovascular Compli-cations of Cancer Therapy: Incidence, Pathogenesis, Diagnosis, and Management. Journal of the American College of Cardiology, 53, 2231-2247.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2009.02.050</mixed-citation></ref><ref id="hanspub.35332-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Coughlin, S., Das, S., Lee, J., et al. (2008) Capecitabine Induced Vasospastic Angina. International Journal of Cardiology, 130, 34-36. &lt;br&gt;https://doi.org/10.1016/j.ijcard.2007.06.152</mixed-citation></ref><ref id="hanspub.35332-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Nieto, Y., Cagnoni, P., Bearman, S.I., et al. (2000) Cardiac Tox-icity Following High Dose Cyclophoph Amide, Cisplatin and BCNU for Breast Cancer. Biology of Blood and Marrow Transplantation, 6, 198-203. 
&lt;br&gt;https://doi.org/10.1016/S1083-8791(00)70043-7</mixed-citation></ref><ref id="hanspub.35332-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Priori, S.G., Blomström-Lundqvist, C., Mazzanti, A., et al. (2015) 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). European Heart Journal, 36, 2793-2867.</mixed-citation></ref><ref id="hanspub.35332-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Skoro-Sajer, N., Hack, N., Sadushi-Koliçi, R., et al. (2009) Pulmonary Vascular Reactivity and Prognosis in Patients with Chronic Thromboembolic Pulmonary Hypertension A Pilot Study. Circulation, 119, 298-305. 
&lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.108.794610</mixed-citation></ref><ref id="hanspub.35332-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Bonderman, D., Skoro-Sajer, N., Jakowitsch, J., et al. (2007) Predictors of Outcome in Chronic Thromboembolic Pulmonary Hypertension. Circulation, 115, 2153-2158. &lt;br&gt;https://doi.org/10.1161/CIRCULATIONAHA.106.661041</mixed-citation></ref><ref id="hanspub.35332-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Jamieson, S.W., Kapelanski, D.P., et al. (2003) Pulmonary Endarterectomy: Experience and Lessons Learned in 1,500 Cases. The Annals of Thoracic Surgery, 76, 1457-1462. &lt;br&gt;https://doi.org/10.1016/S0003-4975(03)00828-2</mixed-citation></ref><ref id="hanspub.35332-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Dartevelle, P., Fadel, E., Mussot, S., et al. (2004) Chronic Thromboembolic Pulmonary Hypertension. European Respiratory Society, 23, 637-648. &lt;br&gt;https://doi.org/10.1183/09031936.04.00079704</mixed-citation></ref><ref id="hanspub.35332-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Ranpura, V., Hapani, S., Chuang, J. and Wu, S. (2010) Risk of Cardiac Ischemia and Arterial Thromboembolic Events with the Angiogenesis Inhibitor Bevacizuab in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials. Acta Oncologica, 49, 287-297. &lt;br&gt;https://doi.org/10.3109/02841860903524396</mixed-citation></ref><ref id="hanspub.35332-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Zangari, M., Fink, L.M., Elice, F., Zhan, F. and Adcock, D.M. (2009) Thrombotic Events in Patients with Cancer Receiving Antiangiogenesis Agents. Journal of Clinical Oncology, 27, 4865-4873.  
&lt;br&gt;https://doi.org/10.1200/JCO.2009.22.3875</mixed-citation></ref><ref id="hanspub.35332-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Bair, S.M., Choueiri, T.K. and Moslehi, J. (2013) Cardiovascular Complications Associated with Novel Angiogenesis Inhibitors: Emerging Evidence and Evolving Perspective. Trends in Cardiovascular Medicine, 23, 104-113. 
&lt;br&gt;https://doi.org/10.1016/j.tcm.2012.09.008</mixed-citation></ref><ref id="hanspub.35332-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Kunihara, T., Gerdts, J., Groesdonk, H., et al. (2011) Predictors of Postoperative Outcome after Pulmonary Endarterectomy from a 14-Year Experience with 279 Patients. European Journal of Cardio-Thoracic Surgery, 40, 154-161.  
&lt;br&gt;https://doi.org/10.1016/j.ejcts.2010.10.043</mixed-citation></ref><ref id="hanspub.35332-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Jaworski, C., Mariani, J.A., Wheeler, G., et al. (2013) Cardiac Complications of Thoracic Irradiation. Journal of the American College of Cardiology, 61, 2319-2328. &lt;br&gt;https://doi.org/10.1016/j.jacc.2013.01.090</mixed-citation></ref><ref id="hanspub.35332-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Hull, M.C., Morris, C.G., Pepine, C.J. and Mendenhall, N.P. (2003) Valvular Dysfunction and Carotid, Subclavian and Coronary Artery Disease in Survivors of Hodgkin Lymphoma Treated with Radiation Therapy. Journal of the American Medical Association, 290, 2831-2837. &lt;br&gt;https://doi.org/10.1001/jama.290.21.2831</mixed-citation></ref><ref id="hanspub.35332-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Hering, D., Faber, L. and Horstkotte, D. (2003) Echocardiographic Features of Radiation-Associated Valvular Disease. American Journal of Cardiology, 92, 226-230. &lt;br&gt;https://doi.org/10.1016/S0002-9149(03)00546-0</mixed-citation></ref><ref id="hanspub.35332-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Vahanian, A., Alfieri, O., Andreotti, F., et al. (2012) Guidelines on the Management of Valvular Heart Disease (Version 2012). European Heart Journal, 33, 2451-2496. &lt;br&gt;https://doi.org/10.1093/eurheartj/ehs109</mixed-citation></ref><ref id="hanspub.35332-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Ogino, H., Ando, M., Matsuda, H., et al. (2006) Japanese Sin-gle-Center Experience of Surgery for Chronic Thrombo-Embolic Pulmonary Hypertension. The Annals of Thoracic Surgery, 82, 630-636. 
&lt;br&gt;https://doi.org/10.1016/j.athoracsur.2006.03.121</mixed-citation></ref><ref id="hanspub.35332-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Mortimer, J.E., Crowley, J., Eyre, H. and Weiden, P. (1992) A Phase II Randomized Study Comparing Sequential and Combined Intraarterial Cisplatin and Radiation Therapy in Primary Brain Tumors. A Southwest Oncology Group Study. Cancer, 69, 1220-1223. &lt;br&gt;https://doi.org/10.1002/cncr.2820690525</mixed-citation></ref><ref id="hanspub.35332-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Kramm, T., Eberle, B., Guth, S., et al. (2005) Inhaled Iloprost to Control Residual Pulmonary Hypertension Following Pulmonary Endarterectomy. European Journal of Cardio-Thoracic Surgery, 28, 882-888.  
&lt;br&gt;https://doi.org/10.1016/j.ejcts.2005.09.007</mixed-citation></ref><ref id="hanspub.35332-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Ghofrani, H.A., D’Armini, A.M., Grimminger, F., et al. (2013) Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. The New England Journal of Med-icine, 369, 319-329. 
&lt;br&gt;https://doi.org/10.1056/NEJMoa1209657</mixed-citation></ref><ref id="hanspub.35332-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Seemann, I., Gillette, K. and Visser, N.L. (2012) Irradiation Induced Modest Changes in Murine Cardiac Function Despite Progressive Structural Damage to the Myocardium and Microvasculature. Radiotherapy and Oncology, 103, 143-150. &lt;br&gt;https://doi.org/10.1016/j.radonc.2011.10.011</mixed-citation></ref><ref id="hanspub.35332-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Stewart, J.R., Fajardo, L.F., Gillette, S.M., et al. (1995) Radia-tion Injury to the Heart. International Journal of Radiation Oncology, Biology, Physics, 31, 1205-1211. &lt;br&gt;https://doi.org/10.1016/0360-3016(94)00656-6</mixed-citation></ref><ref id="hanspub.35332-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">彭毅, 谭文勇. 抗肿瘤治疗相关的心脏血管毒性: 肿瘤心脏病学亟待跟进[J]. 临床与病理杂志, 2015, 35(3): 433-443.</mixed-citation></ref></ref-list></back></article>